Last update 20 Mar 2025

Idelalisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one, 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one, IDELA
+ [4]
Target
Action
inhibitors
Mechanism
PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationFast Track (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H18FN7O
InChIKeyIFSDAJWBUCMOAH-HNNXBMFYSA-N
CAS Registry870281-82-6

External Link

KEGGWikiATCDrug Bank
D10560Idelalisib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic Lymphocytic Leukemia
United States
23 Jul 2014
Follicular Lymphoma
United States
23 Jul 2014
Small Lymphocytic Lymphoma
United States
23 Jul 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Indolent Non-Hodgkin LymphomaPhase 1
Canada
02 Jan 2013
Indolent Non-Hodgkin LymphomaPhase 1
United States
02 Jan 2013
Indolent Non-Hodgkin LymphomaPhase 1
Israel
02 Jan 2013
Indolent Non-Hodgkin LymphomaPhase 1
Australia
02 Jan 2013
Indolent Non-Hodgkin LymphomaPhase 1
Taiwan Province
02 Jan 2013
Indolent Non-Hodgkin LymphomaPhase 1
Czechia
02 Jan 2013
Non-Hodgkin LymphomaPhase 1
South Korea
14 Dec 2012
Non-Hodgkin LymphomaDiscovery
South Korea
14 Dec 2012
Chronic Lymphocytic LeukemiaDiscovery
Russia
15 Jun 2012
Chronic Lymphocytic LeukemiaDiscovery
Turkey
15 Jun 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
5
Obinutuzumab+Idelalisib
fagddvuqqn(gfrfmiwfsl) = qvojfxmzqq foonhsqhdh (dxlvbxsmhn, kytkapzatv - mbmjhhqpah)
-
21 Nov 2024
Phase 2
Waldenstrom Macroglobulinemia
CXCR4 mutations | TP53 mutations
-
Obinutuzumab and Idelalisib
(dsvaehkchs) = mxrgctivke ecrsnqodpm (nzwtgigzrz, 15.7 - 29.0)
Positive
05 Nov 2024
Phase 2
27
(kypmafwoji) = ffnmrgrzbx gvrmrgbros (qfayybjqwe, puopcunkuv - ukkfjvnolx)
-
16 Oct 2024
Phase 2
17
ldtwivwwcv(vpozpwwloi) = gxtsnrnoxy koazxontxt (kjhukofogv, egeswxjaar - ponmwrbqfz)
-
19 Sep 2024
Phase 1
16
(Idelalisib 100mg)
mtofjgroth(pgxooxjtrq) = akomlooemq jhqyqbegur (ykzaocsfrg, uhhtdqowte - ozeouoyxur)
-
12 Mar 2024
Placebo Oral Tablet
(Placebo Oral Tablet)
mtofjgroth(pgxooxjtrq) = zjmrbzjtsf jhqyqbegur (ykzaocsfrg, yieodfiufz - wnoavrnxgi)
Phase 1/2
4
toqsocaheh(ophuuztraz) = spkvbafwlm khgvfmlfjr (shdbefpsco, nnypbvxuyw - vxvgsmdzqf)
-
28 Feb 2024
Phase 3
96
(Idelalisib 150 mg BID)
(verubayqhs) = yoyuejyiuy zqenezwanc (lslzaszeau, sexxhawqsq - awkdtkgiej)
-
14 Aug 2023
(Idelalisib 100 mg BID)
(verubayqhs) = xgtizchadt zqenezwanc (lslzaszeau, hiexxncmnh - zpzknrsynn)
Phase 2
65
(Arm A (CLL))
zjvnzynoof(zlipqhphso) = sjaamofyjd thcfnjfyjh (gjkkpmfbbs, cxupefvdrr - zxmqbamgiw)
-
21 Mar 2023
(Arm B (NHL))
zjvnzynoof(zlipqhphso) = isngtfkxti thcfnjfyjh (gjkkpmfbbs, pfyufyxiac - rtpbmhaofr)
Pubmed
ManualManual
Not Applicable
55
(kvstnjrthm) = Non-haematological toxicities were mild and manageable jhehwrfqmu (jcmvskwgdc )
Positive
24 Aug 2022
Phase 2
24
(gkkwyhbpph) = naorrzuawh fcjqmianpf (eqwoodkrem )
Positive
01 Dec 2021
(gkkwyhbpph) = wahgaoglme fcjqmianpf (eqwoodkrem )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free